CGMP Deviations: Presence of N-nitroso-duloxetine impurity above the recommended interim limit.
Classification
Class II
Status
Ongoing
Lot
Lot DT6023061B Exp 01/31/2025
Date
Disclaimer: This tool indexes published US FDA drug-enforcement recall records from all countries, limited to the latest five years. A company or product not appearing here is not proof that it is compliant, approved, safe, or free of FDA action.